PTCT today
$63.36-$1.55 (-2.39%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourSymmetric Triangle
1 hourStrong Bearish
15 minBearish
5 minLeaning Bearish
Daily trend turns down below $58.80
Key levels
Resistance$70.11
Resistance$65.34
Support$62.13
Support$59.16
Latest news & SEC filings
NewsPTC Therapeutics approves $500 million stock buyback plan
NewsPTC Therapeutics board approves $500M share buyback program
All PTCT news →About PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company that develops and commercializes treatments for rare diseases. Its products include therapies for Duchenne muscular dystrophy, aromatic L-amino acid decarboxylase deficiency, and phenylketonuria. The company sells in the United States, Europe, Latin America, and Japan, and also has research programs in splicing, inflammation, and ferroptosis. Its customers include patients, healthcare providers, and government and private payors.
Based on the company's 10-K filed Feb 19, 2026.
Nasdaq · Healthcare
PTC THERAPEUTICS, INC. (PTCT)
What Is the Price Target for PTCT?
SEPT Low Target
$77.00
SEPT Mid Target
$104.00
SEPT High Target
$137.00
Analyst Consensus
$104.00
Is PTCT a Buy or Sell Right Now?
Thesis
- •Revenue growing 114.5% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PTCT.
Start Free Trial →Is PTCT Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$80.51
19
Moat Score
NONE
6/9
Piotroski Score
1.7
Altman Z-Score
What Is Smart Money Doing with PTCT?
Insider Signal
SELLING
0 buys / 18 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SCHMERTZLER MICHAEL | director | Sale | 2,118 | $126K | Oct 14, 2026 |
| SCHMERTZLER MICHAEL | director | Sale | 382 | $23K | Oct 14, 2026 |
| SCHMERTZLER MICHAEL | director | Sale | 2,447 | $155K | Oct 7, 2026 |
| SCHMERTZLER MICHAEL | director | Sale | 53 | $3K | Oct 7, 2026 |
| Boulding Mark Elliott | officer | Buy | 435 | $17K | Oct 6, 2026 |
| Boulding Mark Elliott | officer | Sale | 435 | $28K | Oct 6, 2026 |
| Boulding Mark Elliott | officer | Buy | 1,638 | $65K | Oct 5, 2026 |
| Boulding Mark Elliott | officer | Sale | 1,638 | $105K | Oct 5, 2026 |
| SCHMERTZLER MICHAEL | director | Sale | 9,624 | $653K | Sep 17, 2026 |
| SCHMERTZLER MICHAEL | director | Sale | 376 | $26K | Sep 17, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PTCT Growth Story
Revenue YoY
114.5%
3yr Revenue CAGR
35.3%
EPS Growth YoY
264.48%
FCF Growth YoY
715.1%
Revenue Trend
ACCELERATING
Dark Pool Trades for PTCT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PTCT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:37 | $63.36 | 2,368 | $$150K | SELL |
| 21:00:34 | $63.36 | 1,188 | $$75K | SELL |
| 21:00:34 | $63.36 | 3,249 | $$206K | SELL |
| 21:00:01 | $63.36 | 1,288 | $$82K | BUY |
| 20:58:40 | $63.34 | 2,262 | $$143K | MIDPOINT |
5 dark pool trades shown · $$656K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for PTC THERAPEUTICS, INC. (PTCT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PTCT — frequently asked questions
What is PTCT stock price today?
PTC THERAPEUTICS, INC. (PTCT) is at $63.36, down 2.39% (-$1.55) at the Nov 12, 2026 close.
Why is PTCT stock moving today?
Latest PTCT news — Nov 3, 2026: PTC Therapeutics approves $500 million stock buyback plan · Nov 3, 2026: PTC Therapeutics board approves $500M share buyback program
What is the PTCT price target?
The average analyst price target for PTCT is $104.00, ranging from $77 to $137, based on 7 analysts. Latest: RBC Capital maintains on Oct 30, 2026.
What do analysts rate PTCT?
Analyst ratings for PTCT: 2 Buy, 15 Hold, 1 Sell — consensus Hold.
Did PTCT beat earnings?
PTCT last reported on Oct 29, 2026: EPS -$0.62 vs $0.14 expected — a miss of 533.3%.
Does PTCT pay a dividend?
PTCT does not currently pay a dividend.
What are PTCT support and resistance levels?
Support: $62.13, $59.16. Resistance: $65.34, $70.11, $73.53.
What are insiders doing with PTCT?
Insider activity: SELLING, 0 buys and 18 sells in the last 90 days.
What is the latest news on PTCT?
Nov 3, 2026: PTC Therapeutics approves $500 million stock buyback plan · Nov 3, 2026: PTC Therapeutics board approves $500M share buyback program